Chimeric anti-IL-17 full-length monoclonal antibody is a novel potential candidate for the treatment of rheumatoid arthritis

Bai,Fuliang; Tian,Hui; Niu,Zeshan; Liu,Mingyao; Ren,Guiping; Yu,Yinhang; Sun,Tian; Li,Siming; Li,Deshan

doi:10.3892/ijmm.2013.1611

Chimeric anti-IL-17 full-length monoclonal antibody is a novel potential candidate for the treatment of rheumatoid arthritis

Authors:
- Fuliang Bai
- Hui Tian
- Zeshan Niu
- Mingyao Liu
- Guiping Ren
- Yinhang Yu
- Tian Sun
- Siming Li
- Deshan Li
View Affiliations

Affiliations: Biopharmaceutical Teaching and Research Section, College of Life Science, Northeast Agricultural University, Harbin, Heilongjiang 150030, P.R. China
Published online on: December 27, 2013 https://doi.org/10.3892/ijmm.2013.1611
Pages: 711-721

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease, primarily manifesting as inflammatory arthritis. It is associated with chronic inflammation of the synovial joints, mostly in the hands and feet, as well as with systemic extra-articular inflammation. The chimeric anti-interleukin (IL)-17 full-length monoclonal antibody (CMa17Aab) targets IL-17A, which is an important cytokine in the pathogenesis of RA and other inflammatory disorders. In this study, we investigated whether CMa17Aab exerts therapeutic effects in a mouse model of type II collagen‑induced arthritis (CIA). Mice with CIA were subcutaneously injected with the humanized CMa17Aab antibody. The effects of treatment were assessed by estimating the arthritis severity score, the extent of histological damage and bone destruction, the autoreactive humoral and cellular immune responses and the production of cytokines. Treatment with CMa17Aab exerted beneficial effects in the mice with CIA as regards clinical and histological parameters. Compared with the controls, treatment with CMa17Aab resulted in a significant alleviation of the severity of the symptoms of arthritis, by preventing bone damage and cartilage destruction, reducing humoral and cellular immune responses, and downregulating the expression of IL-6, IL-8, matrix metalloproteinase (MMP)-3, IL-17, IL-1β, tumor necrosis factor (TNF)-α, receptor activator for nuclear factor-κB ligand (RANKL) and interferon (IFN)-γ in inflamed tissues. In conclusion, our study demonstrates that treatment with CMa17Aab exerts beneficial effects in mice with CIA, by preventing joint inflammation, cartilage destruction and bone damage. These preliminary results suggest that CMa17Aab is an important regulator in RA, and that it may represent a novel therapeutic agent that may prove useful in the treatment of this disease.

View Figures

View References

1	van den Berg WB and Miossec P: IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol. 5:549–553. 2009.PubMed/NCBI
2	Onishi RM and Gaffen SL: Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 129:311–321. 2010. View Article : Google Scholar : PubMed/NCBI
3	Leipe J, Grunke M, Dechant C, et al: Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 62:2876–2885. 2010. View Article : Google Scholar : PubMed/NCBI
4	Maione F, Paschalidis N, Mascolo N, Dufton N, Perretti M and D’Acquisto F: Interleukin 17 sustains rather than induces inflammation. Biochem Pharmacol. 77:878–887. 2009. View Article : Google Scholar : PubMed/NCBI
5	Chen H, Wang W, Xie H, et al: A pathogenic role of IL- 17 at the early stage of corneal allograft rejection. Transpl Immunol. 21:155–161. 2009. View Article : Google Scholar : PubMed/NCBI
6	Hot A, Zrioual S, Lenief V and Miossec P: IL-17 and tumour necrosis factor α combination induces a HIF-1α-dependent invasive phenotype in synoviocytes. Ann Rheum Dis. 71:1393–1401. 2012.
7	Korn T, Bettelli E, Oukka M and Kuchroo VK: IL-17 and Th17 Cells. Annu Rev Immunol. 27:485–517. 2009. View Article : Google Scholar : PubMed/NCBI
8	Chabaud M, Durand JM, Buchs N, et al: Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42:963–970. 1999. View Article : Google Scholar : PubMed/NCBI
9	Kotake S, Udagawa N, Takahashi N, et al: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 103:1345–1352. 1999. View Article : Google Scholar : PubMed/NCBI
10	Chabaud M, Fossiez F, Taupin JL and Miossec P: Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol. 161:409–414. 1998.PubMed/NCBI
11	Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al: IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 160:3513–3521. 1998.PubMed/NCBI
12	Katz Y, Nadiv O and Beer Y: Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a ‘fine-tuning cytokine’ in inflammation processes. Arthritis Rheum. 44:2176–2184. 2001.PubMed/NCBI
13	Kehlen A, Thiele K, Riemann D and Langner J: Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol. 127:539–546. 2002. View Article : Google Scholar : PubMed/NCBI
14	Numasaki M, Lotze MT and Sasaki H: Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett. 93:39–43. 2004. View Article : Google Scholar : PubMed/NCBI
15	Takahashi H, Numasaki M, Lotze MT and Sasaki H: Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett. 98:189–193. 2005. View Article : Google Scholar : PubMed/NCBI
16	Miossec P: Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum. 48:594–601. 2003. View Article : Google Scholar : PubMed/NCBI
17	Granet C, Maslinski W and Miossec P: Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. Arthritis Res Ther. 6:R190–R198. 2004. View Article : Google Scholar : PubMed/NCBI
18	Chabaud M and Miossec P: The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum. 44:1293–1303. 2001. View Article : Google Scholar : PubMed/NCBI
19	Chabaud M, Page G and Miossec P: Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol. 167:6015–6020. 2001. View Article : Google Scholar
20	Granet C and Miossec P: Combination of the pro-inflammatory cytokines IL-1, TNF-alpha and IL-17 leads to enhanced expression and additional recruitment of AP-1 family members, Egr-1 and NF-kappaB in osteoblast-like cells. Cytokine. 26:169–177. 2004. View Article : Google Scholar : PubMed/NCBI
21	Chevrel G, Page G, Granet C, Streichenberger N, Varennes A and Miossec P: Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol. 137:125–133. 2003. View Article : Google Scholar : PubMed/NCBI
22	Kirkham BW, Lassere MN, Edmonds JP, et al: Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 54:1122–1131. 2006.PubMed/NCBI
23	Yao Z, Spriggs MK, Derry JM, et al: Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine. 9:794–800. 1997. View Article : Google Scholar : PubMed/NCBI
24	Tachihara A, Jin E, Matsuoka T, et al: Critical roles of capillary endothelial cells for alveolar remodeling in nonspecific and usual interstitial pneumonias. J Nippon Med Sch. 73:203–213. 2006. View Article : Google Scholar : PubMed/NCBI
25	Tian E, Sawyer JR, Largaespada DA, Jenkins NA, Copeland NG and Shaughnessy JD Jr: Evi27 encodes a novel membrane protein with homology to the IL17 receptor. Oncogene. 19:2098–2109. 2000. View Article : Google Scholar : PubMed/NCBI
26	Shi Y, Ullrich SJ, Zhang J, et al: A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem. 275:19167–19176. 2000. View Article : Google Scholar : PubMed/NCBI
27	Lee J, Ho WH, Maruoka M, et al: IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem. 276:1660–1664. 2001. View Article : Google Scholar : PubMed/NCBI
28	Zrioual S, Toh ML, Tournadre A, et al: IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR⁺ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J Immunol. 180:655–663. 2008. View Article : Google Scholar : PubMed/NCBI
29	Miljkovic D, Cvetkovic I, Vuckovic O, Stosic-Grujicic S, Mostarica Stojkovic M and Trajkovic V: The role of interleukin-17 in inducible nitric oxide synthase-mediated nitric oxide production in endothelial cells. Cell Mol Life Sci. 60:518–525. 2003. View Article : Google Scholar : PubMed/NCBI
30	Lubberts E, Koenders MI, Oppers-Walgreen B, et al: Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50:650–659. 2004. View Article : Google Scholar
31	Genovese MC, Van den Bosch F, Roberson SA, et al: LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62:929–939. 2010. View Article : Google Scholar : PubMed/NCBI
32	Nardelli DT, Burchill MA, England DM, Torrealba J, Callister SM and Schell RF: Association of CD4⁺ CD25⁺ T cells with prevention of severe destructive arthritis in Borrelia burgdorferi-vaccinated and challenged gamma interferon-deficient mice treated with anti-interleukin-17 antibody. Clin Diagn Lab Immunol. 11:1075–1084. 2004.
33	Nakajima H, Takamori H, Hiyama Y and Tsukada W: The effect of treatment with interferon-gamma on type II collagen-induced arthritis. Clin Exp Immunol. 81:441–445. 1990. View Article : Google Scholar : PubMed/NCBI
34	Stuart JM, Townes AS and Kang AH: Type II collagen-induced arthritis. Ann NY Acad Sci. 460:355–362. 1985. View Article : Google Scholar : PubMed/NCBI
35	Toy D, Kugler D, Wolfson M, et al: Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol. 177:36–39. 2006. View Article : Google Scholar : PubMed/NCBI
36	Fan Y, Weifeng W, Yuluan Y, Qing K, Yu P and Yanlan H: Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of coxsackievirus b3-induced viral myocarditis reduces myocardium inflammation. Virol J. 8:172011. View Article : Google Scholar : PubMed/NCBI
37	Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H and Maslinski W: High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol. 164:2832–2838. 2000. View Article : Google Scholar : PubMed/NCBI
38	Bas DB, Su J, Sandor K, et al: Collagen antibody-induced arthritis evokes persistent pain with spinal glial involvement and transient prostaglandin dependency. Arthritis Rheum. 64:3886–3896. 2012. View Article : Google Scholar : PubMed/NCBI
39	Nandakumar KS and Holmdahl R: Collagen antibody induced arthritis. Methods Mol Med. 136:215–223. 2007. View Article : Google Scholar : PubMed/NCBI
40	Yao Z, Painter SL, Fanslow WC, et al: Human IL-17: a novel cytokine derived from T cells. J Immunol. 155:5483–5486. 1995.PubMed/NCBI
41	Miyamoto M, Prause O, Sjostrand M, Laan M, Lötvall J and Lindén A: Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J Immunol. 170:4665–4672. 2003. View Article : Google Scholar : PubMed/NCBI
42	Kennedy J, Rossi DL, Zurawski SM, et al: Mouse IL-17: a cytokine preferentially expressed by alpha beta TCR + CD4-CD8-T cells. J Interferon Cytokine Res. 16:611–617. 1996.
43	Zhang R, Qian J, Guo J, Yuan YF and Xue K: Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody. Curr Eye Res. 34:297–303. 2009. View Article : Google Scholar : PubMed/NCBI
44	Zhang Y, Ren G, Guo M, et al: Synergistic effects of interleukin-1beta and interleukin-17A antibodies on collagen-induced arthritis mouse model. Int Immunopharmacol. 15:199–205. 2013. View Article : Google Scholar : PubMed/NCBI
45	Miossec P: IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect. 11:625–630. 2009. View Article : Google Scholar : PubMed/NCBI
46	Bazzani C, Filippini M, Caporali R, et al: Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev. 8:260–265. 2009. View Article : Google Scholar : PubMed/NCBI
47	Gandjbakhch F, Conaghan PG, Ejbjerg B, et al: Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. J Rheumatol. 38:2039–2044. 2011. View Article : Google Scholar
48	Emery P, McInnes IB, van Vollenhoven R and Kraan MC: Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford). 47:392–398. 2008. View Article : Google Scholar : PubMed/NCBI
49	Hornung N, Ellingsen T, Attermann J, Stengaard-Pedersen K and Poulsen JH: Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. J Rheumatol. 35:1709–1715. 2008.
50	Liu Y, Mei J, Gonzales L, et al: IL-17A and TNF-alpha exert synergistic effects on expression of CXCL5 by alveolar type II cells in vivo and in vitro. J Immunol. 186:3197–3205. 2011. View Article : Google Scholar : PubMed/NCBI
51	Leung S, Liu X, Fang L, Chen X, Guo T and Zhang J: The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol Immunol. 7:182–189. 2010. View Article : Google Scholar : PubMed/NCBI
52	Myers LK, Rosloniec EF, Cremer MA and Kang AH: Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 61:1861–1878. 1997. View Article : Google Scholar : PubMed/NCBI
53	Griffiths MM, Nabozny GH, Hanson J, et al: Collagen-induced arthritis and TCRs in SWR and B10. Q mice expressing an Ek alpha transgene. J Immunol. 153:2758–2768. 1994.PubMed/NCBI
54	Durie FH, Fava RA and Noelle RJ: Collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol. 73:11–18. 1994. View Article : Google Scholar : PubMed/NCBI
55	Nabozny GH, Bull MJ, Hanson J, Griffiths MM, Luthra HS and David CS: Collagen-induced arthritis in T cell receptor V beta congenic B10. Q mice J Exp Med. 180:517–524. 1994. View Article : Google Scholar : PubMed/NCBI
56	Kadowaki KM, Matsuno H, Tsuji H and Tunru I: CD4⁺ T cells from collagen-induced arthritic mice are essential to transfer arthritis into severe combined immunodeficient mice. Clin Exp Immunol. 97:212–218. 1994.